Medical insurance and drug price reform: will slow down the growth rate of the pharmaceutical industry and reduce gross profit
Classification:Talk about the sutras and taoism
Release time:2019-10-21
UBS research believes that the reform of the medical insurance and drug pricing system is the main theme of 2016-2017, which will lead to a slowdown in the growth rate of the pharmaceutical industry and a long-term decrease in gross profit margins.
Due to the government's intensive release of healthcare reform policies, 2016-2017 was known as the year of medical governance. Industry summary: Healthcare reform policies mainly focus on medical insurance and pricing systems, which will have a profound impact on the pharmaceutical industry.
More recommendations